Provided by Tiger Trade Technology Pte. Ltd.

iShares Biotechnology ETF

206.34
+3.941.95%
Volume:545.40K
Turnover:112.59M
Market Cap:10.51B
PE:32.69
High:207.52
Open:205.27
Low:204.81
Close:202.40
52wk High:217.12
52wk Low:138.79
Shares:50.95M
Float Shares:50.95M
Volume Ratio:0.41
T/O Rate:1.07%
Dividend:0.34
Dividend Rate:0.16%
EPS(TTM):6.31
EPS(LYR):35.34
ROE:24.54%
ROA:0.10%
PB:1.29
PE(LYR):5.84

Loading ...

Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Sep 8: Drivers Behind the Movement

TradingKey
·
Sep 09

Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says

MT Newswires Live
·
Sep 09

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines

THOMSON REUTERS
·
Sep 09

Royalty Pharma Falls After Novartis' Cholesterol Drug Fails in Study

Reuters
·
Sep 09

Amgen Pulls Dow Industrials Lower; Oil Jumps on Houthi Strikes in Saudi Arabia

Dow Jones
·
Sep 09

Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon

MT Newswires Live
·
Sep 08

European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading

MT Newswires Live
·
Sep 08

NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-09-08

Reuters
·
Sep 08

Amgen Says Phase 3 Study Meets Primary Endpoint in Small Cell Lung Cancer

MT Newswires Live
·
Sep 08

Amgen Inc Stock (AMGN) Moved Down by 8.33% on Sep 8: A Full Analysis

TradingKey
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Dow Drops 438 Points on Losses for Amgen, Salesforce Shares

Dow Jones
·
Sep 08

Amgen Down Nearly 7%, on Pace for Largest Percent Decrease Since March 2020

Dow Jones
·
Sep 08

Argenx Price Target Maintained with a $1150.00/Share by Wedbush

Dow Jones
·
Sep 08

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Amid Rising Oil Prices

MT Newswires Live
·
Sep 08

Amgen-AstraZeneca Cancer Drug Combo Hits Main Survival Goal in Late-Stage Trial

Reuters
·
Sep 08

AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab

TIPRANKS
·
Sep 08

Sector Update: Healthcare

MT Newswires Live
·
Sep 08

Amgen - Phase 3 Dellphi-305 Study Delivers Significant Overall Survival Benefit Versus Durvalumab Alone

THOMSON REUTERS
·
Sep 08

Imdelltra® in Combination with Imfinzi® Demonstrated Landmark Improvement in Overall Survival in First-Line Extensive Stage Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 08